- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02480101
Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine
June 19, 2015 updated by: Oleg Kiselev, Research Institute of Influenza, Russia
Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Anhui/2013/61 (H7N9) Influenza Vaccine
This is a single centre phase I, double-blind placebo-controlled study to assess reactogenicity, safety and immunogenicity of a live monovalent A/17/Anhui/2013/61 (H7N9) influenza vaccine in healthy male and female adults, 18 through 49 years of age .
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Legal male or female adult 18 through 49 years of age at the enrollment visit.
- Literate and willing to provide written informed consent.
- A signed informed consent.
- Free of obvious health problems, as established by the medical history and screening evaluations, including physical examination.
- Capable and willing to complete diary cards and willing to return for all follow-up visits
- Willing to comply with the rules of the isolation unit (including willing and able to take oseltamivir influenza antiviral medication, should that be recommended by a study physician).
- For females, willing to take reliable birth control measures through day 56.
Exclusion Criteria:
- Participation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study.
- Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to postpone receipt of such vaccines until four weeks after study completion.
- Practice of nasal irrigation on a regular basis within the past six months or has engaged in nasal irrigation within two weeks prior to enrollment.
- Recent history of frequent nose bleeds (more than 5 within the past year).
- Clinically relevant abnormal paranasal anatomy.
- Recent history (within the past month) of rhino or sinus surgery, or surgery for any traumatic injury of the nose.
- Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever.
- Other acute illness at the time of study enrollment.
- Receipt of immune globulin or other blood products within three months prior to study enrollment or planned receipt of such products during the period of subject participation in the study.
- Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment (for corticosteroids, this means prednisone or equivalent, 0.5 mg per kg per day; topical steroids are allowed, exclusive of nasal.)
- Participation in any previous trial of any H7 or H5 containing influenza vaccine.
- History of bronchial asthma.
- Hypersensitivity and allergy reactions after previous administration of any vaccine.
- History of wheezing after past receipt of any live influenza vaccine.
- Other AE following immunization (body temperature more than 40°C, collapse, non-febrile seizures, anaphylaxis), at least possibly related to previous receipt of any vaccine (not only influenza).
- Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein.
- Seasonal (autumnal) hypersensitivity to the natural environment.
- Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, metabolic, neurologic, psychiatric or renal functional abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. Subjects with physical examination findings or clinical laboratory screening results which would be graded 2 or higher on the AE severity grading scale will be excluded from entry into the study and will be excluded from receipt of dose two of study vaccine or placebo.
- History of leukemia or any other blood or solid organ cancer.
- History of thrombocytopenic purpura or known bleeding disorder.
- History of seizures.
- Known or suspected immunosuppressive or immunodeficient condition of any kind, including HIV infection.
- Known chronic HBV or HCV infection.
- Known tuberculosis infection or evidence of previous tuberculosis exposure.
- History of chronic alcohol abuse and/or illegal drug use.
- Claustrophobia or sociophobia.
- Pregnancy or lactation (a negative pregnancy test will be required before administration of study vaccine or placebo for all women of childbearing potential).
- Any condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives.
- Allergic, including anaphylactic, reactions to the introduction of any vaccines in the subject's medical history (not only flu vaccine).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: H7N9 LAIV
H7N9 live influenza vaccine
|
H7N9 live influenza vaccine
Other Names:
|
Placebo Comparator: Placebo
Lyophilized purified allantoic fluid of chicken embryos with stabilizers
|
Lyophilized purified allantoic fluid of chicken embryos with stabilizers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immediate reactions
Time Frame: 2 hours
|
Immediate reactions occurring within two hours of administration of any dose, measured as observed by study staff or reported by the subject to study staff
|
2 hours
|
Solicited adverse events
Time Frame: Greater than two hours after administration of any dose of study vaccine or placebo through 6 days following any dose
|
Adverse events commonly associated with intranasal vaccination (solicited local and systemic reactions), measured as observed by study staff or reported by the subject to study staff
|
Greater than two hours after administration of any dose of study vaccine or placebo through 6 days following any dose
|
Changes from baseline in laboratory findings
Time Frame: Days 3, 6 and 34
|
Abnormal laboratory findings from blood and urine specimens
|
Days 3, 6 and 34
|
Serious adverse events (SAEs)
Time Frame: 4 weeks of receipt of any dose
|
All SAEs during 56 days, as observed by study staff, reported by the subject to study staff, or noted by the subject on a diary card, including abnormal laboratory findings from blood specimens collected on Days 28 (pre-vaccination) and 56
|
4 weeks of receipt of any dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune responses
Time Frame: Days 0, 28 and 56
|
Immune responses was parameterized as the proportion of subjects with at least a four-fold rise after each dose from baseline or as the mean titer after each dose in any of the following:
|
Days 0, 28 and 56
|
Virus shedding
Time Frame: Days 0-6 after each dose
|
Virus shedding with virus detected by real-time reverse transcriptase polymerase chain reaction rRTPCR in nasal swabs at any time point (at day of vaccination and daily during hospitalization).
|
Days 0-6 after each dose
|
Virus stability
Time Frame: Days 0-6 after each dose
|
Virus stability (virus detected and sequenced after inoculation into chicken eggs)
|
Days 0-6 after each dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cellular immune responses (cytokine and T-cell)
Time Frame: Days 0, 28 and 56
|
Cellular immune responses (cytokine and T-cell) was measured using isolated peripheral blood mononuclear cells (PBMCs) tested by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT) assay.
|
Days 0, 28 and 56
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Larisa G Rudenko, MD PhD DSc, Institute of Experimental Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2014
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
June 16, 2015
First Submitted That Met QC Criteria
June 19, 2015
First Posted (Estimate)
June 24, 2015
Study Record Updates
Last Update Posted (Estimate)
June 24, 2015
Last Update Submitted That Met QC Criteria
June 19, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LAIV-H7N9-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on H7N9 live influenza vaccine
-
National Institute of Allergy and Infectious Diseases...University of RochesterCompletedInfluenza A Virus, H7N9 SubtypeUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedAvian Influenza | ImmunisationUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H7N9 SubtypeUnited States
-
University of RochesterNational Institutes of Health (NIH)Withdrawn2009 H1N1 InfluenzaUnited States
-
Hualan Biological Bacterin Co. Ltd.Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionNot yet recruitingInfluenza PreventionChina
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H7N9 SubtypeUnited States
-
Changchun BCHT Biotechnology Co.He Bei province Center for Disease control and preventionRecruitingInfluenza PreventionChina